There are numerous research studies that support the use of PDE inhibitors, in particular the use of inhibitors of isoforms 4 and 5, in pathologies associated with COVID-19, mostly thanks to their well-documented anti-fibrotic and anti-inflammatory effects. Here, ALDH7A1 is linked to COVID-19.